---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Expected outcomes of therapy"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Expected outcomes of therapy. Topics: Goals of on-demand treatment: guidelines, Expected benefit of early treatment: guidelines, Core outcome set for acute treatment trials, Attack duration with and without on-demand treatment: prospective cohorts, and 5 further topics. 9 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Goals of on-demand treatment: guidelines

> “The goal of acute therapy for HAE is to minimize morbidity and prevent mortality from an ongoing angioedema attack.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

> “The aim of treating HAE attacks, also referred to as on-demand therapy, is to minimize the severity and duration of attacks, including potentially fatal upper airway angioedema and associated impairment of quality of life (QoL).”
> “Effective treatment for attacks should not only relieve symptoms but also provide patients with enough time to safely access urgent care if needed.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “The aim of acute treatment of HAE attacks is to prevent mortality and to minimize morbidity by decreasing the duration and severity of symptoms.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

> “We recommend that the goals of treatment are to achieve total control of the disease and to normalize patients' lives.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.7-2"></a>

### Expected benefit of early treatment: guidelines

> “Compared to delayed treatment, early treatment is associated with better outcomes, including faster symptom resolution, shorter episode duration, and greater efficacy, regardless of the severity of the attack.”
> “ODT, regardless of HAE endotype, reduces the risks of asphyxiation, abdominal symptoms, and functional impairment of the limbs.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Studies have shown that treating HAE attacks earlier reduces the total time with swelling symptoms and improves quality of life. People are able to return to their normal activities more rapidly.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

<a id="topic-2.2.2.7-3"></a>

### Core outcome set for acute treatment trials

> “In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.”

Source: [Petersen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38609017/)

<a id="topic-2.2.2.7-4"></a>

### Attack duration with and without on-demand treatment: prospective cohorts

> “Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment (median times from onset 7, 10 and 47 hours, respectively)”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

> “Median attack duration (data available for 2393 attacks) with approved therapies was 10 h, significantly shorter than without treatment (45 h) or with tranexamic acid (38 h).”
> “Median time from onset of symptoms to drug administration was 1 h with icatibant and 2 h with pd-C1INH and median time from drug administration to complete resolution was 5.5 and 8 h, respectively.”

Source: [Zanichelli et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26304015/)

<a id="topic-2.2.2.7-5"></a>

### Time to symptom relief and resolution with oral sebetralstat: phase 3 trial

> “The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.”
> “The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.”

Source: [Riedl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819658/)

<a id="topic-2.2.2.7-6"></a>

### Time to symptom relief with oral sebetralstat during long-term prophylaxis: open-label extension

> “Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.7-7"></a>

### Deucrictibant outcomes in relation to other on-demand agents: RAPIDe-3 discussion

> “Onset of symptom relief was met with a median time of 1·28 h with deucrictibant (compared with >12 h for placebo). In an independent trial of 600 mg oral sebetralstat, onset of symptom relief, measured using the same PGI-C-based endpoint definition, was met with a median time of 1·79 h to 2·0 h (6·72 h to >12 h for placebo).”
> “Variations in trial designs and instruments used across trials for on-demand treatment of hereditary angioedema attacks prevent direct outcome comparisons.”
> “In this trial, complete attack resolution (no symptoms) measured using PGI-S was reached within a median time of 11·95 h with deucrictibant (placebo >48 h).”
> “Treatment with deucrictibant resulted in relatively low use of second capsule (17%) and conventional on-demand therapy as rescue medication (7%) within 12 h, compared with 67% and 36% for placebo, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.7-8"></a>

### Reduced emergency department use with self-administration and on-demand access

> “Data suggest that self-administration of icatibant reduces and delays the need for Emergency Department visits, which are typically required when attacks affect critical anatomical sites.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “In addition, more patients are receiving their HAE treatment at home and the number of hospitalizations and visits to the emergency room for HAE has decreased.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

> “Burden of disease showed significant improvement in all domains except worry about children inheriting HAE.”
> “Nevertheless, our study shows that a substantial burden of illness remains for HAE patients.”

Source: [Christiansen et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25715243/)

<a id="topic-2.2.2.7-9"></a>

### Outcomes after delayed treatment: patient surveys

> “Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).”

Source: [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)

> “When asked how long it usually takes to feel in control of their HAE attacks after on-demand treatment, respondents reported a mean time of 2.2 h (SD: 5.1) post-treatment, with those who treat early (less than 1 h) reporting 1.4 h (SD: 1.1) and those who delay on-demand treatment reporting 2.9 h (SD: 6.7) (Fig. 6).”

Source: [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
